Published in J Pharmacol Exp Ther on February 20, 2008
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther (2009) 1.01
Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci (2010) 0.93
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients. Front Genet (2012) 0.89
Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci (2010) 0.83
Assessment of drug transporter function using fluorescent cell imaging. Curr Protoc Toxicol (2013) 0.80
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmgenomics Pers Med (2012) 0.78
Predictable difficulty or difficulty to predict. Protein Sci (2011) 0.75
Amino acid difference formula to help explain protein evolution. Science (1974) 15.19
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest (1996) 3.75
Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet (2003) 3.37
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther (2004) 2.81
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics (2005) 2.68
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A (1997) 2.10
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci (2001) 1.89
Oral chemotherapy: rationale and future directions. J Clin Oncol (1998) 1.88
Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci (2004) 1.87
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta (1994) 1.64
In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos (2006) 1.50
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther (2000) 1.41
Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J (2006) 1.40
Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol (2002) 1.32
Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem (2002) 1.28
Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem J (2006) 1.23
Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. J Biol Chem (2002) 1.18
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res (2006) 1.18
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol (2002) 1.13
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther (2004) 1.05
Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet (2007) 1.04
Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol (2003) 1.04
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci (2006) 1.03
Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J Biol Chem (1997) 1.02
Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J Biol Chem (1999) 1.02
MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (2005) 1.02
Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res (2004) 1.02
Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol (2004) 0.96
Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci (2007) 0.95
A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci (2006) 0.94
In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics (2006) 0.84
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest (2005) 0.81
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. Anticancer Drugs (2001) 0.80
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics (2005) 2.68
Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep (2007) 2.68
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia (2007) 1.43
Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos (2007) 1.35
Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics (2011) 1.34
Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics (2011) 1.29
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther (2008) 1.23
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet (2007) 1.04
OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics (2013) 1.02
Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res (2004) 1.02
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet (2006) 1.00
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther (2005) 0.98
Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther (2008) 0.96
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One (2009) 0.96
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One (2008) 0.95
Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics (2010) 0.93
Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy (2013) 0.92
Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther (2003) 0.92
Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling. J Pharmacol Exp Ther (2012) 0.92
Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol (2006) 0.90
A survey of integral alpha-helical membrane proteins. J Struct Funct Genomics (2009) 0.89
Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol (2013) 0.89
Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol Regul Integr Comp Physiol (2002) 0.88
Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol (2011) 0.88
Candidate gene approach for pharmacogenetic studies. Pharmacogenomics (2002) 0.87
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics (2013) 0.85
Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family. Biochemistry (2002) 0.84
No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther (2003) 0.84
CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease. J Pharmacol Exp Ther (2006) 0.84
Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci (2010) 0.83
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics (2013) 0.83
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
The effects of ABCB1 3'-untranslated region variants on mRNA stability. Drug Metab Dispos (2007) 0.82
PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network. Pharmacol Rev (2006) 0.79
Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother (2007) 0.78
Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol (2011) 0.78
Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol (2006) 0.77
Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther (2006) 0.76
PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics (2015) 0.76
Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS (2016) 0.75
PharmGKB summary: abacavir pathway. Pharmacogenet Genomics (2014) 0.75
Nicotine metabolism in pregnant and nonpregnant rabbits. Nicotine Tob Res (2008) 0.75
MDR1 reference sequence and reference function. Clin Pharmacol Ther (2002) 0.75
ABCG2 regulatory single-nucleotide polymorphisms alter in-vivo enhancer activity and expression. Pharmacogenet Genomics (2017) 0.75
PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev (2006) 0.75
PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev (2006) 0.75
Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos (2003) 0.75